Compare KeyCorp (KEY) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs ResMed Inc. — how do they compare? KeyCorp trades at $19.98 (market cap $21.45B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and KeyCorp pays the higher dividend (4.08%). Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and ResMed Inc. for 51 Days on average.
| KEY | RMD | |
|---|---|---|
Market Cap | $21.45B | $31.89B |
Volume | 19,450,846 | 618,314 |
Sector | Financials | Health |
52-Week High | $23.99 | $277.88 |
52-Week Low | $16.78 | $182.82 |
Typical Hold Time | 66 Days | 51 Days |
Enterprise Value | $34.63B | $31.24B |
Dividend Yield | 4.08% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.97, up 0.71% with strong recent earnings beats and a 60.79% analyst buy rating. The stock shows bearish technical signals but maintains solid fundamentals with 26.72% net margin and 11.01% ROE. Recent corporate actions include a $0.21 dividend and executive appointments, while cash flow trends show operational stability despite recent net outflows.
KEY presents a compelling value opportunity with 25% upside to consensus target, supported by earnings momentum and dividend stability. Risks include technical bearish pressure, interest rate sensitivity, and competitive dividend landscape. The bank's improved 2026 revenue guidance and institutional accumulation suggest underlying strength despite near-term headwinds.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
